Osteoporosis, a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration, is a significant public health concern. With the aging population, the prevalence of osteoporosis is expected to increase. This article provides an overview of the advancements in the management of osteoporosis, focusing on recent therapeutic options and diagnostic tools.
New imaging techniques have revolutionized the diagnosis of osteoporosis. High-resolution peripheral quantitative computed tomography (HR-pQCT) provides detailed images of the bone microarchitecture, enhancing the prediction of fracture risk. Trabecular bone score (TBS), a texture parameter that evaluates pixel grey-level variations in lumbar spine dual-energy X-ray absorptiometry (DXA) images, is another promising tool that provides additional information about bone quality.
Recent years have witnessed the emergence of novel pharmacological treatments. Anti-sclerostin antibodies, such as romosozumab, increase bone formation and decrease bone resorption, showing a significant reduction in vertebral and non-vertebral fractures. Anabolic agents like Teriparatide and Abaloparatide stimulate bone formation, offering another therapeutic avenue. Moreover, Denosumab, a RANKL inhibitor, has demonstrated superior efficacy in increasing bone mineral density (BMD) and reducing fracture risk.
Non-pharmacological interventions remain integral to osteoporosis management. These include lifestyle modifications such as adequate calcium and vitamin D intake, regular weight-bearing exercise, smoking cessation, and limiting alcohol intake. Furthermore, fall prevention strategies are vital in reducing fracture risk in this population.
The landscape of osteoporosis management is rapidly evolving, with advancements in both diagnostic tools and therapeutic options. These innovations promise a more comprehensive and personalized approach to osteoporosis care. Healthcare professionals need to stay updated with these advancements to optimize patient outcomes and reduce the burden of this debilitating disease.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation